Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 17, 2021
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
Ed Arce Maintained (AKRO) at Strong Buy with Decreased Target to $61 on, Mar 17th, 2021
Ed Arce of HC Wainwright & Co., Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Decreased Target from $64 to $61 on, Mar 17th, 2021.
Ed has made no other calls on AKRO in the last 4 months.
There is 1 other peer that has a rating on AKRO. Out of the 1 peers that are also analyzing AKRO, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Etzer Darout of "Guggenheim" Initiated at Strong Buy and Held Target at $54 on, Friday, February 26th, 2021
